Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
Peptide therapy at Rock Creek Wellness is called Peptide Care. It starts with lab tests and a visit with one of our providers. If a peptide suits you, your provider writes a prescription for you, and a state-licensed pharmacy fills it and ships it to you. We’re a physician-led clinic in Leawood, serving the Kansas City area.
This page is also the front door to our peptide library, where we review the research on the peptides people ask about most. For most of them the research in people is thin, and for some there are no studies in people at all. Each review says so plainly. Our providers prescribe some of these peptides and we earn money from that care, so this page also shows you how the reviews are made.
All of our providers prescribe peptides, Dr. Mark McPhee, Dr. Angela Barnett and Hannah Osborn, APRN among them. Dr. Mark Strehlow, our Medical Director, oversees our standards of care and medically reviews every page of the library.
At a glance
- Who prescribes
- Our own providers, after lab tests and a visit. You don’t choose a peptide from a menu.
- Lab tests
- Before your first visit. Most patients use Quest, and any lab works.
- Your medicine
- Prescribed for you, then dispensed and shipped to you by a state-licensed pharmacy.
- Cost
- $97 a month for your provider’s care. Premier Care members don’t pay this fee. Medicine is a separate cost.
- The library
- Reviews of the research on popular peptides, each medically reviewed, with its FDA status dated.
What peptides are
A peptide is a short chain of amino acids, the same building blocks that make up proteins. The National Human Genome Research Institute puts a peptide at “typically 2 to 50” amino acids; longer chains go on to form proteins.
Peptide therapy means using a peptide as a medicine, and that covers very different things. Semaglutide, the medicine in Ozempic and Wegovy, is a peptide: a modified copy of a hormone called GLP-1. Both are FDA-approved, and semaglutide was tested in large randomized trials. We cover GLP-1 medicines on our medical weight loss page, not here.
Most of the peptides in this library are in a different position. Clinics and sellers promote them for injury recovery, gut complaints, sleep, energy, skin and healthy aging. Few come as an FDA-approved medicine, and most have far less research in people behind them. The word “peptide” tells you what a molecule is made of. It tells you nothing about what the molecule does or how well it has been tested.
How Peptide Care works
- Lab tests. Before your first visit, you have our standard Peptide Care lab panel, which covers what your provider needs to see. Most of our patients go to a Quest Diagnostics lab, but any lab works, and if you’d rather not use insurance, we have discounted cash prices.
- Your visit. You meet one of our providers, who goes through your results with you, along with your health history, your medicines and what you want to address.
- The decision. Your provider decides whether a peptide suits you, and which one. If one does, they write a prescription for you. If none does, they tell you so.
- The pharmacy. We send your prescription to a state-licensed pharmacy. The pharmacy dispenses your medicine and ships it to you, usually the same day, with two-day delivery.
- Follow-up. You see your provider as often as your care needs: follow-up visits aren’t limited. Later lab tests are chosen for you, including for the peptides you take.
Cost
Peptide Care is cash-pay; we don’t bill insurance.
- Each month: $97, billed monthly, for your provider’s care: your visits and follow-ups, with no limit on their number.
- Lab tests: separate. They can go through your insurance at the lab, or you can use our discounted cash prices.
- Your medicine: a separate cost, because it depends on what your provider prescribes. You’ll know the price before anything is prescribed.
- Premier Care members: Peptide Care is included in Premier Care, our most comprehensive program, so there is no added monthly fee. It isn’t part of HRT-Only, our plan for focused hormone care.
You can ask us for a written Good Faith Estimate of your costs before you start.
How we decide whether a peptide makes sense for you
You don’t pick a peptide from a menu here. Your provider decides what fits you, if anything does, and tells you what that decision rests on.
- Your results and your history. Your lab results, your health conditions, the medicines you take and what you want to address.
- What the evidence shows. Trials in people carry the most weight when they exist.
- Where trials are missing. We also look at what has been reported in people, at animal and lab studies, and at what chemistry and physiology suggest. We tell you which kind of evidence a recommendation rests on, including when it is theory.
- Who shouldn’t take it. That differs from one peptide to the next, so each review has its own section on safety and on who shouldn’t use that peptide. It is part of what your provider weighs.
The peptide library
There is one review for each peptide, written for patients and clinicians alike and medically reviewed before it goes live. The table is the short version; each name links to the full review, which covers what the peptide is, where it stands with the FDA, the claims you’ll see online, the evidence at each level, the doses tested in people, and safety.
| Peptide | FDA status | Evidence in people | Doses tested in people | Sport (WADA) |
|---|---|---|---|---|
| AOD-9604 | Not FDA-approved; outside the FDA’s and HHS’s compounding policies. FDA advisers voted 12 to 0 against listing it. | Nine developer-run trials, 993 people, by mouth or vein. No significant benefit over placebo on any main outcome. | 0.25 to 60 mg a day by mouth; single doses by vein. None by injection under the skin. | Prohibited at all times: WADA’s 2026 and 2027 Lists name it among growth hormone fragments (class S2). |
| BPC-157 | Not FDA-approved. A draft HHS policy says it doesn’t intend to act against some compounding; that isn’t approval. | About 88 people given it: two controlled trials, four uncontrolled reports, five in one unblinded pilot. No benefit shown. | Enemas, IV infusion, and knee, bladder or mouth injections. Under the skin: only five people, with a second peptide. | Prohibited at all times; named on the List. |
| CJC-1295 | Not FDA-approved, and outside the FDA’s and HHS’s compounding policies. The FDA’s advisory committee voted against listing it. | Three studies, about 63 healthy volunteers, of the DAC version only; the version usually sold has none. | 30-250 mcg/kg by injection, DAC version only, mostly once; no study set a dose for either molecule. | Prohibited at all times; named on the List. |
| DSIP | Not FDA-approved, and outside the FDA’s and HHS’s compounding policies. | The FDA counts 209 people, into a vein, for 1 to 15 days; the controlled sleep studies ran 1981-1992. | 25-150 nmol/kg into a vein, by the FDA’s count. No study has given it under the skin. | Not named on the 2026 or 2027 List. |
| Epitalon | Not FDA-approved. A draft HHS policy says it doesn’t intend to act against some compounding; that isn’t approval. | Three small studies from the developers’ network: melatonin rose in two; one unblinded eye study. No sleep study. | Into muscle: 0.01 mg a day for 10 days. No milligram-sized injection; none under the skin. | Not named on WADA’s 2026 or 2027 List. WADA says an unnamed peptide “may still be prohibited”. |
| GHK-Cu | Not FDA-approved. For non-injectable forms only, the FDA says it doesn’t intend to act against compounders, under conditions. | On the skin: five randomized trials, with mixed results. Injected on its own: no study in people was found. | Skin products only, for example a 2% serum. None by injection. | Not named on the 2026 or 2027 List. |
| GLOW (GHK-Cu, BPC-157 and TB-500) | Not FDA-approved, and outside the FDA’s and HHS’s compounding policies: HHS’s draft policy applies to single-ingredient products only. | None for the blend. No published study has given the three together to people or to animals. | None for the blend, and no under-the-skin dose of any of its ingredients given alone. | BPC-157 and TB-500 are prohibited at all times and named on the List. GHK-Cu is not named. |
| KLOW (GHK-Cu, KPV, BPC-157 and TB-500) | Not FDA-approved, and outside the FDA’s and HHS’s compounding policies. | None for the blend. KPV, one of its four ingredients, has no published study in people. | None for the blend, at any ratio or by any route. | BPC-157 and TB-500 are prohibited at all times on the 2026 and 2027 Lists. |
| KPV | Not FDA-approved. HHS’s draft policy on compounding names topical and oral KPV acetate only, with conditions. That isn’t approval. | None. No trial, case report or safety study in people has been published, by any route. | None. | Not named on the 2026 or 2027 List. |
| MOTS-c | Not FDA-approved. A draft HHS policy says it doesn’t intend to act against some compounding; that isn’t approval. | None for MOTS-c itself. No published or posted study has given it to a person. | None. | Prohibited at all times; named on the List. |
| PT-141 (bremelanotide) | Approved as Vyleesi for one use in premenopausal women. Compounded bremelanotide, often sold as PT-141, is not FDA-approved. | Two randomized trials of the approved product, 1,267 women: desire and distress improved modestly over placebo. Nausea in 40%. | The approved dose is 1.75 mg under the skin, as needed. | Not named on the 2026 or 2027 List. |
| Selank | Not FDA-approved, and outside the FDA’s and HHS’s compounding policies. | About 200 patients in seven small studies of 14 to 30 days; no placebo-controlled treatment trial found. | 1.8 to 2.7 mg a day for 14 days, by nose where stated. No injected dose was found. | Not named on the 2026 or 2027 List. WADA says an unnamed peptide “may still be prohibited”. |
| Semax | Not FDA-approved. A draft HHS policy names semax (free base) for intranasal use only; that isn’t approval. | Almost all Russian, small, mostly unblinded; none found registered in advance. All gave it by nose. | By nose only. Healthy adults: 0.25 to 1.2 mg. Stroke: 6 to 18 mg a day. None by injection. | Not named on the 2026 List. WADA says an unnamed peptide “may still be prohibited”. |
| SS-31 (elamipretide) | Approved only as Forzinity, for Barth syndrome, under accelerated approval. Compounded or “research” SS-31 is not FDA-approved. | Barth syndrome: the one randomized trial (12 people) missed both main goals. Larger trials in other diseases missed theirs. | The label’s dose: 40 mg under the skin once daily. No injection trial measured an outcome below 4 mg. | Not established: WADA’s full Prohibited List was not searched for elamipretide for this review. |
| TB-500 | Not FDA-approved. A draft HHS policy says it doesn’t intend to act against some compounding; that isn’t approval. | One report of three patients and no trial results. The trials often cited tested thymosin beta-4, a different molecule. | None for TB-500 by injection under the skin or into muscle. | Prohibited at all times; named on the List. |
| Tesamorelin | Approved only as the Egrifta products, for “the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy”. Compounded or “research” tesamorelin is not FDA-approved. | Two main randomized trials, 806 adults with HIV: less visceral fat on CT, weight unchanged. Heart outcomes: not tested. | 2 mg a day (original Egrifta) in approval trials. Current labels: 1.4 mg (Egrifta SV), 1.28 mg (Egrifta WR). | Prohibited at all times; named on the List. |
| Thymosin alpha-1 | Not FDA-approved, and outside the FDA’s and HHS’s compounding policies. | Thousands of trial patients; none of the three largest published placebo-controlled trials showed a benefit on its main outcome. | Usually 1.6 mg under the skin: twice weekly in hepatitis, once or twice daily in intensive care. | Not named on WADA’s 2026 or 2027 List. WADA says an unnamed peptide “may still be prohibited”. |
| Wolverine stack (BPC-157 and TB-500) | Not FDA-approved. A compounded injection combining the two is outside both the FDA’s and HHS’s compounding policies. | No randomized or blinded trial. Three small reports, 12 patients; only three were given TB-500 itself. | No published study has given BPC-157 with TB-500 under the skin or into muscle. No dose-finding study exists. | Both are prohibited at all times on the 2026 and 2027 Lists. |
If you compete in a drug-tested sport, read the last column first. The World Anti-Doping Agency (WADA) prohibits several popular peptides by name at all times, and its note on the 2027 Prohibited List says that “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.”
Where peptides stand with the FDA
Status checked: November 19, 2026.
The short version
A peptide has no status simply because it is a peptide. Each one is in one or more of these positions, and each review says which.
- An FDA-approved medicine. A few peptide medicines are approved for specific uses: Ozempic and Wegovy (semaglutide) and Vyleesi (bremelanotide), for example.
- Compounded by a pharmacy, and not approved. No compounded medicine is FDA-approved. Federal law exempts a drug compounded by a pharmacy from the approval requirement only when its ingredient passes one of three tests. Most of the peptides in this library pass none, and for those the FDA’s guidance says a compounded drug “may violate the FD&C Act.”
- The same, but named in an enforcement policy. For some of those peptides, the FDA or the Department of Health and Human Services (HHS) has said it does not intend to act against pharmacies that compound them under set conditions. That is a statement about enforcement. It is not approval, and it does not change the law above.
- Sold without a prescription as “research use only.” The FDA has told sellers that such products are “unapproved new drugs.”
The rest of this section is the detail behind those four lines.
Compounded medicines
The compounded medicines this page is about are made by a state-licensed pharmacy for one patient, from that patient’s prescription. In HHS’s words: “Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.”
Section 503A of the federal Food, Drug, and Cosmetic Act exempts a compounded drug from three requirements (FDA approval, labeling with adequate directions for use, and current good manufacturing practice) when its conditions are met. One condition concerns the ingredient. It must comply with a United States Pharmacopeia or National Formulary monograph (an official quality standard), or be a component of an FDA-approved drug, or appear on a list the FDA sets by regulation. That list has six entries, and none is a peptide. A pharmacy also may not compound “regularly or in inordinate amounts” products that are “essentially copies of a commercially available drug product.”
Of the peptides reviewed here so far, only bremelanotide passes one of those tests: it is a component of an approved drug, Vyleesi. For an ingredient that passes none, the FDA’s guidance says a drug compounded from it “is not eligible for the exemptions in section 503A and may violate the FD&C Act.”
Two enforcement policies
For some ingredients that pass none of the tests, an agency has said when it does not intend to act. Neither policy is an approval, and neither changes section 503A.
The FDA’s Category 1
While its list is being developed, the FDA keeps interim categories of substances that were nominated for it. For a substance in Category 1, the FDA “does not intend to take action against a compounder” when the conditions in its guidance are met. Category 2 holds substances for which “FDA has identified significant safety risks.”
HHS’s draft interim policy on six peptides
On October 30, 2026, HHS announced a draft “Enforcement Discretion Policy” that names six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. In the notice announcing it, HHS says it “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician” compounding one of them, and the policy applies only when all of its conditions are present. Among them:
- One ingredient. The product contains “only a single Active Pharmaceutical Ingredient” from the policy’s list.
- Set identity and route. The peptide has the identity, and the limits on route of administration, that the policy sets out for it.
- A tested ingredient. It comes from an FDA-registered facility with a certificate of analysis.
- The label. Its labeling includes the statement “This is a compounded drug product. Not for resale.”
- One patient. The drug is compounded for one patient, from a prescription.
HHS states that intention “Until a peptide bulk drug substance is addressed in a final rule as being included or not included on the 503A bulks list.” Its notice calls the policy both a “draft” and an “interim policy,” gives no effective date, and says it “does not establish any rights for any person and is not binding on HHS or the public.” HHS also says it “may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises.” No final version had been published in the Federal Register when we last checked.
The FDA’s safety concerns
Neither policy means the FDA has reviewed a compounded peptide for safety or effectiveness. The FDA has published the safety concerns it has identified for each of the six peptides in HHS’s draft policy and for several outside it. Of BPC-157, for example, it writes that compounded drugs containing it “may pose risk for immunogenicity for certain routes of administration” (an unwanted immune reaction) and that “the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.” Each review quotes what the FDA has said about its peptide.
State pharmacy rules
Each state sets its own pharmacy rules, and neither policy changes them. Kansas’s rule on nonsterile compounding, which governs forms taken by mouth or put on the skin, says a pharmacist “shall not compound a nonsterile preparation” by “compounding finished drugs from bulk active ingredients that are not components of FDA-approved drugs,” and it reaches preparations shipped into Kansas. When we last checked, the Kansas Board of Pharmacy’s guidance documents said nothing on how it applies that rule to these peptides.
Products sold as “research use only”
Peptides are also sold online without a prescription, labelled “research use only” or “not intended for human consumption.” The FDA has sent warning letters to sellers of such products, calling the products “unapproved new drugs” and writing that “injectable drug products can pose risks of serious harm to users.”
How these reviews are made
Our providers prescribe some of these peptides, so you should know what our own interest is and how the reviews are made.
Our interest. Rock Creek Wellness’s providers prescribe some of the peptides reviewed here, and we earn money from that care.
Every statement about what a peptide does carries its level of evidence. Each review labels what it says a peptide does with one of five levels, in these words:
- Tested in people: trials, randomized controlled trials first, then other studies in people. We write “shown” only for a result from a controlled trial, and we give each study’s size, design and funder. A study tells you what happened to the people in it, at the dose and by the route it used. It may not carry over to a different dose, a different route or a different molecule.
- Reported in people: case reports, uncontrolled series, surveys, and what clinicians and patients report. These are uncontrolled, so they can’t separate the peptide from everything else.
- Animal studies. They can show what a peptide does in an animal and what would be worth testing in people. They can’t show that the same thing happens in people.
- Lab studies (cells, tissue). They can show how a peptide acts on cells or tissue in a dish. They can’t show what it does in a body.
- Theory: reasoned from mechanism, chemistry or physiology, with the reasoning shown. It is a reason to test something, not a result.
A finding at levels 3 to 5 is described as what it is and is never worded as a benefit you will get. Where there are no studies, a review says “not tested.” That is different from “doesn’t work,” and it cuts both ways: not shown to help, and not shown to be safe.
Facts are checked against their sources. Each review rests on an evidence file. Before a word of the review was drafted, a second, separate pass went back to that file’s sources and checked its numbers and quotations against them: all of those on regulatory status, how the body handles the peptide, studies in people, doses, safety and product quality, and at least a third of the sourced statements on what the peptide is, how it works and animal and lab studies. Anything that couldn’t be opened or confirmed was marked as unverified, and a review either leaves it out or says it is unverified. Every review lists its sources.
Who does the work. The evidence files, the second pass that checks them and the first drafts are all done with AI research tools, working to the rules on this page. Dr. Mark Strehlow, our Medical Director, reviews each page before it goes live, and the judgment in each review’s “What we make of it” section is ours.
Status is dated. “Status checked” on a review is the date we last read the FDA and HHS sources. We re-check every review every three months, and whenever the FDA or HHS acts.
Doses are reported, not advised. A dose appears only as what a named study gave, or as a convention in circulation that is labelled as one no study set. The pages carry no mixing or injection instructions, because a dose is a prescriber’s decision for one patient.
Corrections are welcome. If you think a review gets something wrong, tell us through our contact form. Name the review and the statement, and give your source; for a journal article, its PubMed ID or DOI is enough. We check every report against the sources, and when a review is wrong, we correct it.
Common questions
Is peptide therapy like Ozempic?
In one sense. Semaglutide, the medicine in Ozempic and Wegovy, is a peptide, so taking it is a kind of peptide therapy. But Ozempic and Wegovy are FDA-approved and were tested in large randomized trials, and most of the peptides in our library are not and were not. If a GLP-1 medicine is what you’re looking for, see our medical weight loss page.
Are peptides FDA-approved?
Some peptide medicines are: Ozempic and Wegovy (semaglutide) and Vyleesi (bremelanotide), for example. Most of the peptides in our library are not. A compounded peptide is never FDA-approved, whichever peptide it is, because the FDA doesn’t review compounded drugs before they’re sold. Each review gives its peptide’s status and the date we checked it.
Do I need a prescription for peptides?
For a peptide medicine from a pharmacy, yes. The compounded peptides this page is about are made by a pharmacy for one patient, from that patient’s prescription, and the approved peptide medicines named on this page are prescription drugs. For compounded peptides, section 503A’s conditions are written for whoever compounds the drug. The federal sources we read don’t say that writing the prescription violates the Food, Drug, and Cosmetic Act, and they don’t say that prescribers are outside it; prescribing itself is governed by state law.
Can I buy peptides online without a prescription?
They are sold that way, labelled “research use only” or “not intended for human consumption.” The FDA has told sellers that such products are “unapproved new drugs” and that “injectable drug products can pose risks of serious harm to users.” Each review’s section on product quality reports what tests of such products have found.
Does peptide therapy work?
That depends on the peptide. Some peptide medicines have large randomized trials behind them; semaglutide is one. For most of the popular peptides in our library, trials like that haven’t been done, and each review lays out what evidence there is and how strong it is.
What are the risks of peptide therapy?
They differ by peptide, so each review has its own section on safety and on who shouldn’t use it. Some things hold for all of them. The FDA doesn’t review a compounded drug before it’s sold, and HHS notes that compounded drugs “also may pose risks to patients.” The concerns the FDA has published about these peptides include an unwanted immune reaction and impurities left from making the peptide. And for a peptide with few or no studies in people, side effects and long-term risks have been measured little or not at all.
Do I need lab tests?
Yes. Here, you have lab tests before your provider prescribes anything.
Does insurance cover peptide therapy?
Peptide Care is cash-pay, and we don’t bill insurance. Your lab tests can go through your insurance at the lab, or you can use our discounted cash prices.
How long until I notice a difference?
There is no one honest number, and we won’t promise one. Where a trial in people measured how soon an effect appeared, the review reports it. Where no trial did, any timeline you read is someone’s impression, not a measurement.
Which peptide is best?
None is best in general, and we don’t rank them. It depends on what you want to address and on what the evidence shows for that use, which each review lays out. Here, your provider decides what fits you, if anything does.
Sources
Show all 14 sourcesHide sources
- Peptide. National Human Genome Research Institute.
- OZEMPIC (semaglutide) injection: prescribing information. DailyMed (U.S. National Library of Medicine), 2026.
- WEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablet: prescribing information. DailyMed (U.S. National Library of Medicine), 2026.
- VYLEESI (bremelanotide injection): prescribing information. DailyMed (U.S. National Library of Medicine), 2026.
- 21 U.S. Code § 353a – Pharmacy compounding. Cornell Law School.
- 21 CFR 216.23: Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act. Electronic Code of Federal Regulations, 2026.
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration, 2025.
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration, 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, 2026.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. U.S. Department of Health and Human Services, 2026.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026.
- Gram Peptides – 721806 – 03/31/2026. U.S. Food and Drug Administration, 2026.
- K.A.R. 68-13-3, Nonsterile preparations. Kansas Secretary of State, 2018.
- The Prohibited List. World Anti-Doping Agency, 2026.
